Intermediate‐dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease‐free survival

Tapan K. Saikia, Suresh H. Advani, Gopal Ramakrishnan, Shanti Swaroop, Sanjay Sharma, Praful B. Desai

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Seventeen patients with inoperable locoregional disease (epidermoid carcinoma of the esophagus) were treated only with two courses of intermediate‐dose methotrexate (200 mg/m2 on day 1) and cisplatin (20 mg/m2/d for 5 days). According to the response criteria, 14 (82.4%) achieved a good response (GR) and 3 (17.6%) showed no response (NR). The median recurrence‐free survival time was 5 months (range, 2 to 16 months) in seven patients with regular follow‐up. Three patients are still alive and disease‐free at 37+, 44+, and 51+ months. No patient received radiotherapy or surgery after chemotherapy until recurrence. This combination schedule appears to be effective in advanced esophageal carcinoma.

Original languageEnglish (US)
Pages (from-to)371-373
Number of pages3
JournalCancer
Volume64
Issue number2
DOIs
StatePublished - Jul 15 1989

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intermediate‐dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease‐free survival'. Together they form a unique fingerprint.

  • Cite this